445 related articles for article (PubMed ID: 30381374)
1. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
[TBL] [Abstract][Full Text] [Related]
2. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
[TBL] [Abstract][Full Text] [Related]
3. Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial.
Tallon D; Wiles N; Campbell J; Chew-Graham C; Dickens C; Macleod U; Peters TJ; Lewis G; Anderson IM; Gilbody S; Hollingworth W; Davies S; Kessler D
Trials; 2016 Feb; 17():66. PubMed ID: 26842107
[TBL] [Abstract][Full Text] [Related]
4. Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial.
Rifkin-Zybutz R; MacNeill S; Davies SJ; Dickens C; Campbell J; Anderson IM; Chew-Graham CA; Peters TJ; Lewis G; Wiles N; Kessler D
J Psychopharmacol; 2020 Dec; 34(12):1342-1349. PubMed ID: 33143538
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
[TBL] [Abstract][Full Text] [Related]
7. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.
Lewis G; Duffy L; Ades A; Amos R; Araya R; Brabyn S; Button KS; Churchill R; Derrick C; Dowrick C; Gilbody S; Fawsitt C; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Khan N; Lanham P; Pervin J; Peters TJ; Riozzie D; Salaminios G; Thomas L; Welton NJ; Wiles N; Woodhouse R; Lewis G
Lancet Psychiatry; 2019 Nov; 6(11):903-914. PubMed ID: 31543474
[TBL] [Abstract][Full Text] [Related]
9. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A; Bitter I; Buyze J; Cebulla K; Frey R; Fu DJ; Ito T; Kambarov Y; Llorca PM; Oliveira-Maia AJ; Messer T; Mulhern-Haughey S; Rive B; von Holt C; Young AH; Godinov Y;
N Engl J Med; 2023 Oct; 389(14):1298-1309. PubMed ID: 37792613
[TBL] [Abstract][Full Text] [Related]
10. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
[TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial.
Wiles N; Thomas L; Abel A; Barnes M; Carroll F; Ridgway N; Sherlock S; Turner N; Button K; Odondi L; Metcalfe C; Owen-Smith A; Campbell J; Garland A; Hollinghurst S; Jerrom B; Kessler D; Kuyken W; Morrison J; Turner K; Williams C; Peters T; Lewis G
Health Technol Assess; 2014 May; 18(31):1-167, vii-viii. PubMed ID: 24824481
[TBL] [Abstract][Full Text] [Related]
12. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
Banerjee S; Hellier J; Romeo R; Dewey M; Knapp M; Ballard C; Baldwin R; Bentham P; Fox C; Holmes C; Katona C; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; Orrell M; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Burns A
Health Technol Assess; 2013 Feb; 17(7):1-166. PubMed ID: 23438937
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of mirtazapine as add-on to paroxetine
Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
[TBL] [Abstract][Full Text] [Related]
14. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
Edwards SJ; Hamilton V; Nherera L; Trevor N
Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
[TBL] [Abstract][Full Text] [Related]
15. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
16. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial.
Duffy L; Bacon F; Clarke CS; Donkor Y; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Lewis G; Mangin D; Marston L; Moore M; Nazareth I; Wiles N; Lewis G
Trials; 2019 Jun; 20(1):319. PubMed ID: 31159856
[TBL] [Abstract][Full Text] [Related]
18. Antidepressants for people with epilepsy and depression.
Maguire MJ; Marson AG; Nevitt SJ
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD010682. PubMed ID: 33860531
[TBL] [Abstract][Full Text] [Related]
19. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
